Biofund, Quintiles to expand clinical advancement services in Russia Russian Venture Organization Biofund, a Russian-based investment strong, and Quintiles, the world’s leading biopharmaceutical providers company, today announced a definitive contract to aid expansion of medical development solutions within the Russian Federation, the world’s ninth most populous nation. With a populace of nearly 140 million, Russia is usually under-represented with regards to clinical advancement activity and over-represented in term of unmet medical requirements, said Ben Negatives, Global Vice President, Quintiles Corporate Advancement. Quintiles’ objective is to handle both of these issues together with RVC Biofund, which includes experience in starting businesses in capital and Russia to purchase the biopharma sector long effect .
Biofactory introduces FastFraX FMR1 Identification Kit in MEDICA 2012 The Biofactory, a biomedical incubator located in Singapore, has launched a fresh genetic test at MEDICA 2012, the world's largest medical trade good. Known as FastFraX, this genetic check will be able to effectively display for Fragile X Syndrome , a genetic condition this is the most common type of inherited intellectual disability. This fresh test is designed for the global study community and The Biofactory is definitely proactively calling genetic laboratories and study organisations across European countries. The underlying technology for FastFraX originated by experts from the National University of Singapore . A group led by Associate Professor Samuel Chong, from the Section of Paediatrics of the NUS Yong Loo Lin College of Medication, developed highly-delicate genetic probes for detecting the genetic mutation connected with FXS.